Keywords: فارماکودینامیک; Clinical trial; Pilot; Training concept; Pharmacokinetic; Pharmacodynamic; Feasibility; ACE; Angiotensin-converting-enzyme; Cmax; maximum serum concentration; ELISA; Enzyme-linked immunosorbent assay; EMA; European Medicines Agency; EU; European Union; FD
مقالات ISI فارماکودینامیک (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: فارماکودینامیک; Alfentanil; Endoscopy; Midazolam; Opioid; Pharmacodynamic;
Keywords: فارماکودینامیک; Pharmacokinetic; Pharmacodynamic; Study design; Drug movement;
Keywords: فارماکودینامیک; Aβ1-42; 42-amino acid-long Aβ peptide; AD; Alzheimer's disease; ADAPT; Alzheimer's Disease Anti-Inflammatory Prevention Trial; ADAS-Cog; Alzheimer's Disease Assessment Scale-Cognitive Subscale; ADCS-ADL; Alzheimer's Disease Cooperative Study Activ
Keywords: فارماکودینامیک; BTZ; bortezomib; CFZ; carfilzomib; C-L; caspase-like; CNS; central nervous system; CT-L; chymotrypsin-like; CYPs; cytochrome P450 enzymes; iP; immunoproteasome; IXZ; ixazomib; MM; multiple myeloma; OPZ; oprozomib; PD; pharmacodynamic; PI; proteasome inhib
Keywords: فارماکودینامیک; Arzneimittel; Lebensmittel; Wechselwirkungen; Pharmakokinetik; Pharmakodynamik; Geschmacksstörungen; Bioverfügbarkeit; Cytochrom-P450-System; Grapefruit; Milchprodukte; Alkohol; Tyramin; Goji Beeren; Koffein; Vitamin K; Drugs; foodstuffs; interactions;
Keywords: فارماکودینامیک; Pharmacodynamic; Chewed; Crushed; VerifyNow; Platelet; Aggregation;
Quantitative estimation of cholinesterase-specific drug metabolism of carbamate inhibitors provided by the analysis of the area under the inhibition-time curve
Keywords: فارماکودینامیک; AChE; acetylcholinesterase (EC 3.1.1.7); ADME; absorption, distribution, metabolism, excretion; AUC; area under the concentration-time curve; AUIC; area under the inhibition-time curv; BChE; butyrylcholinesterase (EC 3.1.1.8); BTCh; butyrylthiocholine; DT
Keywords: فارماکودینامیک; Cocaine; Discrimination; Benzphetamine; Rhesus monkey; Pharmacokinetic; Pharmacodynamic;
Keywords: فارماکودینامیک; Detomidine; Yohimbine; Pharmacokinetic; Pharmacodynamic; Behavioral change;
Keywords: فارماکودینامیک; Glibenclamide; Solid lipid nanoparticles; Controlled release; Bioavailability; Pharmacodynamic;
Keywords: فارماکودینامیک; 1,5-AG; 1,5-anhydroglucitol; AUC; area under curve; CGM; Continuous Glucose Monitoring; CI; confidence interval; CONGAn; Continuous Overlapping Net Glycemic Action; CV; Coefficient of Variance; DCCT; Diabetes Control and Complication Trial; FPG; fasting p
Keywords: فارماکودینامیک; API; active pharmaceutical ingredient; BE; bioequivalence; CLSM; confocal laser scanning microscopy; DDS; drug delivery system; ELISA; enzyme-linked immunosorbent assay; EMA; European Medicines Agency; FDA; U.S. Food & Drug Administration; FITC; fluoresce
Keywords: فارماکودینامیک; BMI; body mass index; G; gauge (of needle); GDM; gestational diabetes; HCP; healthcare professional; ID; intradermal; IM; intramuscular; ITQ; Injection Technique Questionnaire; NPH; neutral protamine Hagedorn (Humulin® N, Novolin® N); PD; pharmacodynami
Keywords: فارماکودینامیک; alfentanil; gastrointestinal endoscopy; midazolam; pharmacodynamic; response surface model
Keywords: فارماکودینامیک; RPPA; Proteomics; Biomarker; Drug development; Pharmacodynamic;
Keywords: فارماکودینامیک; pulmonary; tissue partition; pharmacokinetics; pulmonary drug delivery; distribution; Cu,cell; intracellular unbound drug concentration; Cu,lungISF; unbound drug concentration in the lung interstitial fluid; fu,lung; fraction of unbound drug in diluted lu
Keywords: فارماکودینامیک; Metabolomics; Pharmacokinetic; Pharmacodynamic; Rhein; Rhubarb; UPLC-QTOF/MS; Ultra performance liquid chromatography - micromass quadrupole - time of flight mass spectrometry; UPLC-MS/MS; Ultra performance liquid chromatography - triple quadrupole tandem
Keywords: فارماکودینامیک; Human health risk assessment; Toxicokinetic; Toxicodynamic; Pharmacokinetic; Pharmacodynamic; Chemical specific adjustment factor (CSAF); Bioaccumulation; Bioavailability; Cmax; Area under the curve (AUC)
Keywords: فارماکودینامیک; DCX; docetaxel; PK; phamacokinetic; PD; pharmacodynamic; HPLC; high-performance liquid chromatography; UV; ultraviolet; MS/MS; tandem mass spectrometry; UPLC; ultra-performance liquid chromatography; MTBE; methyl t-butyl ether; LC; liquid chromatography;
Keywords: فارماکودینامیک; Antimicrobial; drug interactions; elderly; pharmacodynamic; pharmacokinetic; polypharmacy
Keywords: فارماکودینامیک; pharmacodynamic; pharmacokinetic; platelets; ST-segment elevation myocardial infarction; ticagrelorACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; AUC, area under the curve; Cmax, maximal observed plasma concentration; HPR, high on-
Keywords: فارماکودینامیک; postoperative pain; multimodal analgesia; personalized medicine; pharmacokinetic; pharmacodynamic; pharmacogenetic; pharmacogenomic;
Keywords: فارماکودینامیک; drug dosing; obesity; pediatric; pharmacodynamic; pharmacokinetic;
Keywords: فارماکودینامیک; ADA; Anti-drug antibody(ies); ADCC; Antibody-dependent cellular cytotoxicity; AE; Adverse event; CBA; Cell-based assay; CDC; Complement dependent cytotoxicity; CLB; Competitive ligand binding; EIP; European Immunogenicity Platform; EIP-AWG; European Immun
Keywords: فارماکودینامیک; Modithromycin; EDP-420; Pharmacodynamic; Streptococcus pneumoniae; Pneumococci
Keywords: فارماکودینامیک; Piperacillin/tazobactam; Infection; Intensive care; Prolonged infusion; Pharmacokinetic; Pharmacodynamic;
Keywords: فارماکودینامیک; omega-3 fatty acids; antidepressants; fluoxetine; forced swimming test; depression; drug effects; drug-like properties; pharmacodynamic; preclinical pharmacokinetic; physiological model;
Keywords: فارماکودینامیک; Vancomycin; Continuous infusion; Therapeutic drug monitoring; Pharmacodynamic; Pharmacokinetic; Efficacy; Toxicity; Stability; Compatibility;
Keywords: فارماکودینامیک; 3Rs; replacement, refinement and reduction of animals in research; ACSA; Agricultural Chemicals Safety Assessment; ADA; anti-drug antibody; CNS; central nervous system; DBS; dried blood spot; DART; developmental and reproductive toxicity; DRF; dose range
Keywords: فارماکودینامیک; AUC; area under the curve; BW; body weight; Cant50; tolerance “concentration”; CLKC; nicotine renal clearance; CLMC; nicotine metabolic clearance; COTCL; total cotinine clearance (unscaled); COTCLC; total cotinine clearance (scaled); CVVB; blood nicot
Keywords: فارماکودینامیک; Clozapine efficacy; Pharmacogenetics; Pharmacodynamic; Serotonergic genes; Weight gain
Morning administration of 0.4Â U/kg/day insulin glargine 300Â U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100Â U/mL in type 1 diabetes
Keywords: فارماکودینامیک; Insulin degludec; Insulin glargine; Pharmacodynamic; Pharmacokinetic; Type 1 diabetes; GIR-AUC0-24; area under the GIR over time curve; GIR-smFL0-24; fluctuation of the smoothed glucose infusion rate; LOESS; locally weighted regression in smoothing sc
Enhancement of the dissolution and bioavailability from freeze-dried powder of a hypocholesterolemic drug in the presence of Soluplus
Keywords: فارماکودینامیک; ACUC; animal care and use committee; DSC; differential scanning electron microscope; EZT; ezetimibe; EZT-D4; deuterated ezetimibe; FD-EZT; freeze-dried ezetimibe; FTIR; Fourier transform infrared spectroscopy; PHY; physical mixture of ezetimibe and solupl
Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis
Keywords: فارماکودینامیک; Alpha-mannosidosis; Velmanase alfa; Enzyme-replacement therapy; Global treatment response model; OMIM 248500; Enzyme Commission number: 3.2.1.24; 3MSCT; 3-min stair climb test; 6MWT; 6-min walking test; BMI; body mass index; BOT-2; Bruininks-Oseretsky Tes
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria
Keywords: فارماکودینامیک; AUC; area under the curve; BA; bioavailability; CLplasma; plasma clearance; CLint; intrinsic clearance; CYP; cytochrome P450; DCM; dichloromethane; DMF; dimethyl formamide; ED; effective dose; FaSSIF; fasted state simulated intestinal fluid; FeSSIF; fed s
Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases
Keywords: فارماکودینامیک; AUClast; Area under concentration-time curve; CL; Total clearance; COLO205; Intestinal epithelial cells; Cmax; Maximal serum concentration; DC; Dendritic Cells; DMEM; Dulbecco's modified Eagle's medium; DSS; Dextran sulfate sodium salt; EC50; Half max
Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes
Keywords: فارماکودینامیک; RO; receptor occupancy; EPS; extrapyramidal symptoms; PK; pharmacokinetic; PD; pharmacodynamic; EM; extensive metabolizer; IM; intermediate metabolizer; PM; poor metabolizer; PBPKPD; physiology-based pharmacokinetic and pharmacodynamic; P-gp; P-glycoprote
Safety and Biosimilarity of ior®LeukoCIM Compared to Neupogen® Based on Toxicity, Pharmacodynamic, and Pharmacokinetic Studies in the Sprague-Dawley Rat
Keywords: فارماکودینامیک; biosimilar; filgrastim; ior®LeukoCIM; pharmacodynamic; pharmacokinetic; safety;
ASP0028 in combination with suboptimal-dose of tacrolimus in Cynomolgus monkey renal transplantation model
Keywords: فارماکودینامیک; AUC(0-24); the area under the plasma concentration-time curves from 0 to 24Â h; Cmax; the maximum plasma concentration; CNI; calcineurin inhibitor; MS; multiple sclerosis; MST; median survival time; NHPs; nonhuman primates; PD; pharmacodynamic; PK; phar
Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study
Keywords: فارماکودینامیک; β2-agonist; Cardiovascular; Safety; COPD; BDP; beclometasone dipropionate; DBP; diastolic blood pressure; DPI; dry powder inhaler; FDC; fixed-dose combination; FF; formoterol fumarate; PD; pharmacodynamic; pMDI; pressurised metered-dose inhaler; QTcF; QT
sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain
Keywords: فارماکودینامیک; SPD; sec-butylpropylacetamide; VPA; valproic acid; CAPs; compound action potentials; AED; antiepileptic drugs; SNL; spinal nerve ligation; PK; pharmacokinetic; PD; pharmacodynamic; VFF; von-Frey filaments; MC; methyl cellulose; TPE; time to peak effect; A
P2Y12 Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease
Keywords: فارماکودینامیک; antithrombotic; avatar mice; microfluidics; neonates; shunt thrombosis; ADP; adenosine diphosphate; ATE; acute thromboembolic events; CHD; congenital heart disease; EC50; the concentration of a drug that gives half-maximal response; IC50; the concentratio
Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents
Keywords: فارماکودینامیک; Ac; acetyl; ADME; absorption, distribution, metabolism, and excretion; aq.; aqueous; AUC; total area under the blood concentration-time curve; bid; bis in die (twice per day); Boc; (tert-butoxy)carbonyl; Bu; butyl; Bz; benzoyl; cLogP; calculate logarith
Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential
Keywords: فارماکودینامیک; ADME; absorption, distribution, metabolism, and excretion; AML; acute myelogenous leukemia; AUC; area under the blood concentration time curve; b.i.d.; twice a day; CDK; Cyclin-dependent kinase; CLtotal; clearance; Cmax; maximum drug concentration; CRC; c
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data
Keywords: فارماکودینامیک; ABCC1/MRP; ATP binding cassette subfamily C member 1/ multidrug resistance protein; ABVD; doxorubicine-bleomycin-vinblastine-dacarbazine; AC; doxorubicin-cyclophosphamide; ANC; absolute neutrophil count; ASCO; American Society of Clinical Oncology; AUC; a
Validated low-volume aldosterone immunoassay tailored to GCLP-compliant investigations in small sample volumes
Keywords: فارماکودینامیک; Aldosterone; Immunoassay; Pediatric; Pharmacodynamic; Validation; Low-volume;
Development of nabumetone loaded lipid nano-scaffold for the effective oral delivery; optimization, characterization, drug release and pharmacodynamic study
Keywords: فارماکودینامیک; Nabumetone; NLC; Osteoarthritis; Carrageenan; Box-Behnken; Pharmacodynamic;
Quelle place pour la modélisation dans les essais cliniques en psychiatrie ?
Keywords: فارماکودینامیک; Modélisation; Pharmacocinétique; Pharmacodynamique; Nonmem; Régression non-linéaire à effets mixtes; LOCF; MMRM; Modeling; Pharmacokinetics; Pharmacodynamic; Nonmem; Non-linear mixed effects modeling; Last Observation Carried Forward;
Design and synthesis of fused bicyclic inhibitors targeting the L5 loop site of centromere-associated protein E
Keywords: فارماکودینامیک; DIPEA; N,N-diisopropylethylamine; HATU; hexafluorophosphate O-(7-azabenzotriazol-1-yl)-N,N,Nâ²,Nâ²-tetramethyluronium; PD; pharmacodynamic; CENP-E; Electrostatic potential map (EPM); 2,3-Dihydro-1-benzothiophene 1,1-dioxide derivatives; Anti-cancer agen